Economic evaluation in critical care: a focus on severe sepsis in oncology

References

• Cancer facts and figures 2005. American Cancer Society, Atlanta, GA, USA (2005).
   Google Scholar
• Sahyoun JR, Lentzner H, Hoyert D, Robinson KN. Trends in causes of death among the elderly. US Centers for Disease Control and Prevention, National Center for Health Statistics (2005).
   Google Scholar
• Heffler S, Smith S, Keehan S et al. Health spending projections through 2013. Health Aff, Web Exclusive, W4–79–93 (2004).
   Google Scholar
• Ginsburg PG. Controlling health care costs. N. Engl. J. Med. 351(16), 1591–1593 (2004).
   PubMedGoogle Scholar
• Aday L, Begley CE, Lairson DR, Balkrishnan R. In: Evaluating the Healthcare System. Health Administration Press, IL, USA (2004).
   Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Drummond M, McGuire A. Economic Evaluation in Health Care. Oxford University Press, Oxford, UK (2001).
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds.). Cost-Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Smith MD, Berger ML, Bingefors K et al. (Eds). Health Care Cost, Quality, and Outcomes, ISPOR Book of Terms. International Society for Pharmacoeconomics and Outcomes Research, USA (2003).
   Google Scholar
• Wood KA, Angus DC. Pharmacoeconomic implications of new therapies in sepsis. Pharmacoeconomics 22(14), 895–906 (2004).
   PubMed Web of Science ®Google Scholar
• Wernerman J, Flaatten H. The problem with reporting the cost of intensive care. Acta Anaesthesiol. Scand. 48, 933–934 (2004).
   PubMed Web of Science ®Google Scholar
• Holt AE, Slonim AD. Caveats of evaluating costs in critical care. Crit. Care Med. 32(1), 299–300 (2004).
   Google Scholar
• Understanding costs and cost–effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research. Am. J. Respir. Crit. Care Med. 165(4), 540–550 (2002).
   Google Scholar
• Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit. Care Med. 31(1 Suppl.), S7–S16 (2003).
   Google Scholar
• Jegers M, Edbrooke DL, Hibbert CL, Chalfin DB, Burchardi H. Definitions and methods of cost assessment: an intensivist’s guide. ESICM section on health research and outcome working group on cost effectiveness. Intensive Care Med. 28(6), 680–685 (2002).
   Google Scholar
• Pines JM, Fager SS, Milzman DP. A review of costing methodologies in critical care studies J. Crit. Care 17(3), 181–186 (2002).
   Google Scholar
• Shorr AF. An update on cost–effectiveness analysis in critical care. Curr. Opin. Crit. Care 8(4), 337–343 (2002).
   PubMedGoogle Scholar
• Wilson K, Cook DJ. Economics and the intensive care unit: a conflict of interests? J. Crit. Care 12(3), 147–151 (1997).
   Google Scholar
• Heyland DK. Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit. Care Med. 24(9), 1591–1598 (1996).
   Google Scholar
• Gyldmark M. A review of cost studies of intensive care units: problems with the cost concept. Crit. Care Med. 23, 964–972 (1995).
   PubMed Web of Science ®Google Scholar
• Edbrooke D, Hibbert C, Ridley S, Long T, Dickie H. The development of a method for comparative costing of individual intensive care units. Anaesthesia 54, 110–120 (1999).
   Google Scholar
• Edbrooke DL, Ridley SA, Hibbert CL, Corcoran M. Variations in expenditure between adult general intensive care units in the UK. Anaesthesia 56(3), 208–216 (2001).
   PubMed Web of Science ®Google Scholar
• Parviainen I, Herranen A, Holm A, Uusaro A, Ruokonen E. Results and costs of intensive care in a tertiary university hospital from 1996–2000. Acta Anaesthesiol. Scand. 48(1), 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Flaatten H, Kvale R. Cost of intensive care in a Norwegian University hospital 1997–1999. Crit. Care 7(1), 72–78 (2003).
   PubMed Web of Science ®Google Scholar
• Stricker K, Rothen HU, Takala J. Resource use in the ICU: short- vs. long-term patients. Acta Anaesthesiol. Scand. 47(5), 508–515 (2003).
   PubMed Web of Science ®Google Scholar
• Graf J, Graf C, Janssens U. Analysis of resource use and cost-generating factors in a German medical intensive care unit employing the Therapeutic Intervention Scoring System (TISS-28). Intensive Care Med. 28(3), 324–331 (2002).
   Google Scholar
• Iapichino G, Radrizzani D, Simini B et al. Effectiveness and efficiency of intensive care medicine: variable costs in different diagnosis groups. Acta Anaesthesiol. Scand. 48(7), 820–826 (2004).
   Google Scholar
• Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. A model to compute the medical cost of patients in intensive care. Pharmacoeconomics 15(6), 573–582 (1999).
   PubMed Web of Science ®Google Scholar
• Graf J, Wagner J, Graf C, Koch K-C, Janssens U. Five-year survival, quality of life, and individual costs of 303 consecutive medical intensive care patients – a cost–utility analysis. Crit. Care Med. 33(3), 547–555 (2005).
   PubMed Web of Science ®Google Scholar
• Moran JL, Peisach AR, Solomon PJ, Martin J. Cost calculation and prediction in adult intensive care: a ground-up utilization study. Anaesth. Intensive Care 32(6), 787–797 (2004).
   Google Scholar
• Edbrooke D, Stevens VG, Hibbert CI, Mann AJ, Wilsom AJ. A new method of accurately identifying costs of individual patients in intensive care: the initial results. Intensive Care Med. 23, 645–650 (1997).
   Google Scholar
• Neilson AR, Moerer O, Burchardi H, Schneider H. A new concept for DRG-based reimbursement of services in German intensive care units: results of a pilot study. Intensive Care Med. 30(6), 1220–1223 (2004).
   Google Scholar
• Rapoport J, Teres D, Zhao Y, Lemeshow S. Length of stay data as a guide to hospital economic performance for ICU patients. Med. Care 41(3), 386–397 (2003).
   PubMed Web of Science ®Google Scholar
• Chelluri L, Mendelsohn AB, Belle SH et al. Hospital costs in patients receiving prolonged mechanical ventilation: does age have an impact? Crit. Care Med, 31(6), 1746–1751 (2003).
   Google Scholar
• Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29(7), 1303–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Parrillo JE, Parker MM, Natanson C et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113(3), 227–242 (1990).
   PubMed Web of Science ®Google Scholar
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20(6), 864–874 (1992).
   PubMed Web of Science ®Google Scholar
• Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol. Oncol. Clin. North Am. 7(4), 771–793 (1993).
   PubMedGoogle Scholar
• Williams MD, Braun LA, Cooper LM et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit. Care 8(5), R291–R298 (2004).
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. [Erratum appears in Crit. Care Med. 32(6),1448 (2004). Note: Correction of dosage error in text]. Crit. Care Med. 32(3), 858–873 (2004).
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118, 146–155 (2000).
   PubMed Web of Science ®Google Scholar
• Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic threatment in patients with bloodstream infection. J. Intern. Med. 244, 379–386 (1998).
   PubMed Web of Science ®Google Scholar
• Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am. J. Med. 68, 344–355 (1980).
   PubMedGoogle Scholar
• McCabe WR, Jackson GG. Gram-negative bacteremia. Arch. Intern. Med. 110, 92–100 (1962).
   Google Scholar
• Bodey GP. Infection in cancer patients: a continuing association. Am. J. Med. 81(Suppl. 1A), 11–26 (1986).
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730–751 (2002).
   PubMed Web of Science ®Google Scholar
• Yadegarynia D, Tarrand J, Raad I, Rolston KVI. Current spectrum of bacterial infections in cancer patients. Clin. Infect. Dis. 37, 1144–1145 (2004).
   Google Scholar
• Raad I, Escalante C, Hachem R et al. Treatment of febrile neutropenic cancer patients requiring hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98, 1039–1047 (2003).
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Charpentier C et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7), 862–871 (2002).
   PubMed Web of Science ®Google Scholar
• Briegel J, Forst H, Haller M et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med. 27(4), 723–732 (1999).
   PubMed Web of Science ®Google Scholar
• Bollaert PE, Charpentier C, Levy B et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med. 26(4), 645–650 (1998).
   PubMed Web of Science ®Google Scholar
• Winquist EW, Laskey J, Crump M, Khamsi F, Shepherd FA. Ketoconazole in the management of paraneoplastic Cushing’s syndrome secondary to ectopic adrenocorticotropin production. J. Clin. Oncol. 13(1), 157–164 (1995).
   Web of Science ®Google Scholar
• Sharkey PK, Rinaldi MG, Dunn JF et al. High-dose itraconazole in the treatment of severe mycoses. Antimicrob. Agents Chemother. 35(4), 707–713 (1991).
   PubMed Web of Science ®Google Scholar
• Gradon JD, Sepkowitz DV. Fluconazole-associated acute adrenal insufficiency. Postgrad. Med. J. 67(794), 1084–1085 (1991).
   Google Scholar
• Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit. Care Med. 29(3), 668–670 (2001).
   PubMed Web of Science ®Google Scholar
• Azcona C, Sierrasesumaga L. Adrenal suppression in children with malignant solid tumors treated with megestrol acetate. J. Pediatr. 137(1), 141–142 (2000).
   Google Scholar
• Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344(10), 699–709 (2001).
   PubMed Web of Science ®Google Scholar
• Personal communication. Data on File, Eli Lilly and Company (October 2005).
   Google Scholar
• Pastores SM, Shaw A, Williams MD et al. A safety evaluation of drotrecogin alfa (activated) in hematopoietic stem cell transplant patients with severe sepsis: lessons in clinical research. Bone Marrow Transplant. 36(8), 721–724 (2005).
   PubMed Web of Science ®Google Scholar
• van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345(19), 1359–1367 (2001).
   PubMed Web of Science ®Google Scholar
• Esmatjes E, Ricart MJ, Ferrer JP et al. Cyclosporine’s effect on insulin secretion in patients with kidney transplants. Transplantation 52(3), 500–503 (1991).
   PubMed Web of Science ®Google Scholar
• Jain A, Reyes J, Kashyap R et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann. Surg. 230(3), 441–448 (1999).
   PubMed Web of Science ®Google Scholar
• Mehta RL, McDonald B, Gabbai FB et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney International 60(3), 1154–1163 (2001).
   PubMed Web of Science ®Google Scholar
• Kellum JA, Angus DC, Johnson JP et al. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med. 28(1), 29–37 (2002).
   PubMed Web of Science ®Google Scholar
• Kapoor M, Chan GZ. Malignancy and renal disease. Crit. Care Clin. 17(3), 571–598 (2001).
   PubMed Web of Science ®Google Scholar
• Braun L, Riedel AA, Cooper LM. Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J. Manage. Care Pharm. 10(6), 521–530 (2004).
   Google Scholar
• Schmid A, Pugin J, Chevrolet JC et al. Burden of illness imposed by severe sepsis in Switzerland. Swiss Med. Wkly 134(7–8), 97–102 (2004).
   PubMedGoogle Scholar
• Jacobson S, Johansson G, Winso O. Primary sepsis in a university hospital in northern Sweden: a retrospective study. Acta Anaesthesiol. Scand. 48(8), 960–967 (2004).
   Google Scholar
• Lee H, Doig CJ, Ghali WA et al. Detailed cost analysis of care for survivors of severe sepsis. Crit. Care Med. 32(4), 981–985 (2004).
   Google Scholar
• Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality and medical care charges in patients with severe sepsis. Crit. Care Med. 31(9), 2316–2323 (2003).
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med. 29(9), 1464–1471 (2003).
   PubMed Web of Science ®Google Scholar
• Yu DT, Black E, Sands KE et al. Severe sepsis: variation in resource and therapeutic modality use among academic centers. Crit. Care 7(3), R24–R34 (2003).
   Google Scholar
• Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J. Crit. Care, 17(1), 39–49 (2002).
   Google Scholar
• Schmid A, Schneider H, Adlof A et al. Economic burden of illness imposed by severe sepsis in Austria. Wien Klin. Wochenschr. 114(15–16), 697–701 (2002).
   PubMed Web of Science ®Google Scholar
• Schmid A, Burchardi H, Clouth J, Schneider H. Burden of illness imposed by severe sepsis in Germany. Eur. J. Health Econ. 3, 77–82 (2002).
   PubMedGoogle Scholar
• Moerer O, Schmid A, Hofmann M et al. Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med. 28(10), 1440–1446 (2002).
   PubMed Web of Science ®Google Scholar
• Edbrooke DL, Hibbert CL, Kingsley JM et al. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit. Care Med. 27(9), 1760–1767 (1999).
   PubMed Web of Science ®Google Scholar
• Williams MD, Braun L, Cooper LM et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated cots of care. Critical Care 8, R291–R298 (2004).
   PubMed Web of Science ®Google Scholar
• Davies A, Ridley S, Hutton J et al. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom. Anaesthesia 60(2), 155–162 (2005).
   PubMed Web of Science ®Google Scholar
• Angus DC, Linde-Zwirble WT, Clermont G et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit. Care Med. 31(1), 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Betancourt M, McKinnon PS, Massanari RM et al. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 21(18), 1331–1340 (2003).
   Google Scholar
• Fowler RA, Hill-Popper M, Stasinos J et al. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J. Crit. Care 18(3), 181–191 (2003).
   PubMed Web of Science ®Google Scholar
• Neilson AR, Burchardi H, Chinn C et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. [Erratum appears in J. Crit. Care 19(1), 66 (2004).] J. Crit. Care 18(4), 217–227 (2003).
   PubMed Web of Science ®Google Scholar
• Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347(13), 993–1000 (2002).
   PubMed Web of Science ®Google Scholar